Patients with and without diabetes and acute bacterial skin and skin structure infections (ABSSSI) experience similar rates of clinical response when treated with dalbavancin, according to research presented at IDWeek 2017 in San Diego, California.
Investigators at Allergan plc and the UCLA Medical Center Department of Emergency Medicine conducted a double-blind, phase 3 trial of adult patients (n=698; 10.9% with diabetes; 89.1% without) with ABSSSI, defined as a major abscess, cellulitis, or traumatic wound or surgical site infection. Participants received either a single or 2-dose dalbavancin regimen (1500 mg or 100 mg on day 1 and 500 mg on day 8) in a 1:1 randomization. Primary study end point was 20% or greater reduction in erythema at 48 to 72 hours. A post hoc analysis compared outcomes between patients with and without diabetes.
Participants in the diabetes group had higher rates of cellulitis, and those without diabetes had higher rates of abscesses. Clinical success (improvement in lesion size, signs, and symptoms) at days 14 and 28 was achieved in more than 84% of participants with diabetes, and more than 95% of that group also achieved investigator assessment of cure. Fifty-one participants with and without diabetes (n=7 and 44, respectively) experienced drug-related adverse events.
“Dalbavancin has similar rates of clinical response and success for the treatment of ABSSSI in patients with or without diabetes,” the researchers concluded.
Disclosures: All authors are employees of Allergan plc.
Nowak M, Rappo U, Gonzalez PL, et al. Efficacy and safety of dalbavancin for the treatment of acute bacterial skin and skin structure infection (ABSSSI) in patients with diabetes mellitus. Presented at: IDWeek 2017; October 4-8, 2017; San Diego, CA. Abstract 210.
This article originally appeared on Infectious Disease Advisor